➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Express Scripts
McKinsey
Johnson and Johnson
Mallinckrodt

Last Updated: July 27, 2021

DrugPatentWatch Database Preview

Patent: 5,736,524

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 5,736,524
Title: Polynucleotide tuberculosis vaccine
Abstract:Genes encoding Mycobacterium tuberculosis (M.tb) proteins were cloned into eukaryotic expression vectors to express the encoded proteins in mammalian muscle cells in vivo. Animals were immunized by injection of these DNA constructs, termed polynucleotide vaccines or PNV, into their muscles. Immune antisera was produced against M.tb antigens. Specific T-cell responses were detected in spleen cells of vaccinated mice and the profile of cytokine secretion in response to antigen 85 was indicative of a T.sub.h 1 type of helper T-cell response (i.e., high IL-2 and IFN-.gamma.). Protective efficacy of an M.tb DNA vaccine was demonstrated in mice after challenge with M. bovis BCG, as measured by a reduction in mycobacterial multiplication in the spleens and lungs of M.tb DNA-vaccinated mice compared to control DNA-vaccinated mice or primary infection in naive mice.
Inventor(s): Content; Jean (Rhode-Saint-Genese, BE), Huygen; Kris (Brussels, BE), Liu; Margaret A. (Rosemont, PA), Montgomery; Donna (Chalfont, PA), Ulmer; Jeffrey (Chalfont, PA)
Assignee: Merck & Co.,. Inc. (Rahway, NJ) N. V. Innogenetics S.A. (Ghent, BE)
Application Number:08/338,992
Patent Claims:see list of patent claims

Details for Patent 5,736,524

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ⤷  Try it Free Merck & Co.,. Inc. (Rahway, NJ) N. V. Innogenetics S.A. (Ghent, BE) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ⤷  Try it Free Merck & Co.,. Inc. (Rahway, NJ) N. V. Innogenetics S.A. (Ghent, BE) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ⤷  Try it Free Merck & Co.,. Inc. (Rahway, NJ) N. V. Innogenetics S.A. (Ghent, BE) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 5,736,524

Country Patent Number Estimated Expiration
South Africa 959608 ⤷  Try it Free
World Intellectual Property Organization (WIPO) 9615241 ⤷  Try it Free
United States of America 2002032162 ⤷  Try it Free
United States of America 6384018 ⤷  Try it Free
Slovakia 283254 ⤷  Try it Free
Slovakia 59797 ⤷  Try it Free
Russian Federation 2186109 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Mallinckrodt
McKesson
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.